Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT02768298

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02768298
  • EudraCT 2015-004632-35
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02768298. Randomized; double masking; primary purpose treatment. Start 2016-07-12 (actual); primary completion 2019-11-25 (actual). Results posted on 2020-10-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
Intervention (Drug)
LCZ696
Intervention (Drug)
Enalapril
Intervention (Drug)
Placebo matching enalapril
Intervention (Drug)
Placebo matching LCZ696
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02768298
Content hash
024f8e2b0a8750f656a7499b2f7f65ca43e375c93b1889d510c171de8bd23b24